FAITH TRIALS

FAITH Trials by Glenmark Pharmaceuticals Ltd.

The new combination clinical trial will be called FAITH – (FA vipiravir plus Um I fenovir (efficacy and safety) Trial in Indian Hospital setting.

FAITH Trials by Glenmark Pharmaceuticals Ltd.

Top Current Affairs 27th May 2020

Source | The Hindu


GS Paper III: Science and Technology – developments and their applications and effects in everyday life Achievements of Indians in science & technology; indigenization of technology and developing new technology.



FAITH TRIALS

Key Takeaways

  • The new combination clinical trial will be called FAITH – (FA vipiravir plus Um I fenovir (efficacy and safety) Trial in Indian Hospital setting.
  • Both the Favipiravir and Umifenovir inhibited virus infection in vitro and have shown efficacy in COVID-19 trials.

Read More: Hydroxychloroquine and Frontline Workers


Context: Keeping an eye on the rising number of COVID-19 patients in India, Glenmark Pharmaceuticals Ltd. will conduct ‘FAITH’ trials to test combined efficacy of two antiviral drugs — Favipiravir and Umifenovir — as potential COVID-19 treatment strategy.

What you should know about this ‘FAITH TRIALS’?

  • The new combination clinical trial will be called FAITH – (FA vipiravir plus Um I fenovir (efficacy and safety) Trial in Indian Hospital setting.
  • The two antiviral drugs have different mechanisms of action, and their combination may demonstrate improved treatment efficacy by effectively tackling high viral loads in patients during early stages of the disease.
  • As many as 158 hospitalised patients of moderate COVID-19 infection will be enrolled in the combination study and randomised in two groups.
  • Both the Favipiravir and Umifenovir inhibited virus infection in vitro and have shown efficacy in COVID-19 trials.
  • The current study will examine whether early administration of a combination of Favipiravir and Umifenovir enhances anti-viral efficacy on COVID-19 patients.
  • Hence, a combined use of Favipiravir and Umifenovir acting on different mechanisms offers a comprehensive antiviral cover on pre-entry and post-entry life-cycle of the SARS-COV-2 virus.


Read More: Clinical trials (PHASE-3) on Favipiravir for COVID-19


Details about Favipiravir and Umifenovir

FAVIPIRAVIR

  • Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections.
  • It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014.
  • In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China.
  • It became a generic drug in 2019.
  • In February 2020, favipiravir was being studied in China for experimental treatment of the emergent COVID-19.
  • The drug has been approved for use in clinical trials of coronavirus disease 2019 in China.
  • In March 2020, Italy approved the drug for experimental use against COVID-19 and has begun conducting trials in three regions most affected by the disease.

UMIFENOVIR

  • Umifenovir sold under brand name Arbidol is an antiviral treatment for influenza infection used in Russia and China.
  • The drug is manufactured by Pharmstandard.
  • It is not approved by the US FDA for the treatment or prevention of influenza.
  • The drug is claimed to inhibit viral entry into target cells and stimulate the immune response.
  • Interest in the drug has been renewed as a result of the COVID-19 pandemic.


Also Read: Adenovirus COVID-19 vaccine (Ad5-nCoV)


Subscribe to our newsletter!


INDIATHINKERS is now on TELEGRAM as ExamGuideUpsc. Join our Channel to get the latest posts updates and other important quiz and pdf materials.



Print Friendly, PDF & Email